

type of report	Current report
number	32/2012
company	PHARMENA

Entering into an agreement on bioavailability testing

The Management Board of PHARMENA S.A. informs that on 12th July 2012, its subsidiary company Cortria Corp. (USA) entered into an agreement with Bio Pharma Services Inc. on carrying out bioavailability testing of anti-atherosclerosis medicinal product 1-MNA (working name of the product TRIA-662).

Bioavailability testing determines the time and levels of absorption of medicinal substance into the general circulation of human organism after single administration. A bioavailability testing on a group of 20 patients is planned. It will focus on two testing groups: 1-MNA vs. niacin (active substance used in currently sold anti-atherosclerotic medicines).

Bioavailability testing is indispensable for carrying out further clinical trials of innovative anti-atherosclerotic medicinal product based on active substance 1-MNA.

Bio Pharma Services Inc. is a research centre specializing in bioavailability and bioequivalence testing commissioned by pharmaceutical companies from, among others, USA, Canada and Europe. For more information, please visit www.biopharmaservices.ca.

Entering into the above agreement lies within the realisation of the Company's updated Strategy for 2012-2015 in the scope of anti-atherosclerosis medicinal product project (the Issuer informed about the strategy's assumptions in current report no. 16/2012 of 13th April 2012).

The information is made public due to the fact that the execution of the above agreement is of significant importance for the commercialisation of the anti-atherosclerosis medicinal product project, and potential revenue from it may have considerable influence on financial results and market valuation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board